All In Biotech

Drug Trial Radar · NCT02301130

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Nov 26, 2014

Primary completion

Dec 8, 2017

Study completion Mar 5, 2018

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Nov 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumors

Interventions

  • mogamulizumabBiological

    Mogamulizumab will be administered intravenously (IV).

  • MEDI4736 (Durvalumab)Biological

    MEDI4736 will be administered intravenously (IV).

  • tremelimumabBiological

    Tremelimumab will be administered intravenously (IV).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects reporting adverse eventsTime frame: Screening through 90 days after the last dose of study medication
  2. Number of subjects reporting serious adverse eventsTime frame: Screening through 90 days after the last dose of study medication
  3. Percentage of subjects reporting serious adverse eventsTime frame: Screening through 90 days after the last dose of study medication
  4. Percentage of subjects reporting adverse eventsTime frame: Screening through 90 days after the last dose of study medication
  5. Number of subjects experiencing dose-limiting toxicityTime frame: First dose of study medications through 4 weeks after the last dose of study medication

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The Angeles Clinic

    Los Angeles, California

  • UCLA Hematology & Oncology Clinic

    Los Angeles, California

  • Yale Cancer Center

    New Haven, Connecticut

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Georgia Cancer Center

    Augusta, Georgia

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.